Atlas Trials

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Clinical trial NCT05225116 · UNKNOWN

Trial details

NCT number
NCT05225116
Sponsor
Beijing Tsinghua Chang Gung Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2023-01-08
Primary completion
2025-12-05
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.